Loading financials from SEC filings…
Biotechnology · Healthcare · Fiscal year ends Dec 31
CRISPR Therapeutics reported revenue of $4M in the fiscal year ended Dec 2025, down 90.6% from the year before. Operating income was −$665M, an operating margin of −18933.6%, and net income was −$582M. Operating cash flow of −$345M less capital expenditure of $914,000 left free cash flow of −$346M. It held more cash than debt (net cash $348M).
Ranks among the 30 biotechnology companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 915 | 1.2 | 371 | 37.3 | 3.5 |
| Research & development | 341 | 462 | 387 | 310 | 285 |
| Operating income | 374 | −673 | −223 | −467 | −665 |
| Pre-tax income | 380 | −651 | −151 | −363 | −578 |
| Income tax | 1.9 | −0.3 | 2.9 | 3.6 | 3.6 |
| Net income | 378 | −650 | −154 | −366 | −582 |
| Diluted EPS | 4.70 | −8.36 | −1.94 | −4.34 | −6.47 |
| Diluted shares | 80.4 | 77.7 | 79.2 | 84.4 | 89.9 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 923 | 212 | 389 | 298 | 348 |
| Receivables | 0.3 | 0.0 | 200 | 25.0 | 0.0 |
| Current assets | 2,418 | 1,853 | 1,908 | 1,937 | 1,986 |
| Net PP&E | 138 | 164 | 152 | 134 | 116 |
| Total assets | 2,752 | 2,243 | 2,230 | 2,242 | 2,265 |
| Payables | 14.8 | 27.4 | 38.1 | 14.7 | 11.1 |
| Deferred revenue | 1.0 | 0.0 | 4.1 | 3.8 | 15.8 |
| Current liabilities | 120 | 121 | 109 | 87.8 | 149 |
| Long-term debt | – | – | – | – | 0.0 |
| Total liabilities | 352 | 368 | 347 | 310 | 343 |
| Shareholders' equity | 2,399 | 1,875 | 1,883 | 1,932 | 1,922 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | 539 | −496 | −260 | −143 | −345 |
| Capital expenditure | 81.7 | 37.2 | 9.5 | 1.9 | 0.9 |
| Free cash flow | 457 | −533 | −270 | −145 | −346 |
| Depreciation & amortisation | 18.0 | 24.2 | 19.8 | 19.3 | 19.5 |
| Stock-based compensation | 102 | 97.9 | 81.0 | 86.6 | 72.5 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | −99.9% | 30885.5% | −89.9% | −90.6% |
| Operating income growth (YoY) | – | −280.2% | – | – | – |
| EPS growth (YoY) | – | −277.9% | – | – | – |
| Operating margin | 40.8% | −56190.4% | −60.0% | −1250.4% | −18933.6% |
| Net margin | 41.3% | −54271.7% | −41.4% | −981.5% | −16569.8% |
| Return on equityBlank when equity is negative | 15.7% | −34.7% | −8.2% | −19.0% | −30.3% |
| ROCEEBIT ÷ (assets − current liabilities) | 14.2% | −31.7% | −10.5% | −21.7% | −31.4% |
| Free cash flow margin | 50.0% | −44484.9% | −72.7% | −387.7% | −9855.5% |
| Cash conversion (CFO ÷ net income) | 1.43x | 0.76x | 1.70x | 0.39x | 0.59x |
| Receivable days | 0 | 0 | 197 | 245 | 0 |
| Debt ÷ equity | – | – | – | – | 0.00x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | – | – | – | – | −348 |
| Current ratio | 20.2x | 15.3x | 17.5x | 22.1x | 13.3x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.